Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.

Cancer J

From the *Department of Medical Oncology, Dana-Farber Cancer Institute; †Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; and ‡Massachusetts General Hospital Cancer Center, Boston; and §Broad Institute of MIT and Harvard, Cambridge, MA.

Published: May 2017

Historically, immune-based therapies have played a leading role in the treatment of hematologic malignancies, with the efficacy of stem cell transplantation largely attributable to donor immunity against malignant cells. As new and more targeted immunotherapies have developed, their role in the treatment of hematologic malignancies is evolving and expanding. Herein, we discuss approaches for antigen discovery and review known and novel tumor antigens in hematologic malignancies. We further explore the role of established and investigational immunotherapies in hematologic malignancies, with a focus on personalization of treatment modalities such as cancer vaccines and adoptive cell therapy. Finally, we identify areas of active investigation and development. Immunotherapy is at an exciting crossroads for the treatment of hematologic malignancies, with further investigation aimed at producing effective, targeted immune therapies that maximize antitumor effects while minimizing toxicity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856170PMC
http://dx.doi.org/10.1097/PPO.0000000000000257DOI Listing

Publication Analysis

Top Keywords

hematologic malignancies
24
treatment hematologic
12
antigen discovery
8
role treatment
8
hematologic
6
malignancies
6
discovery therapeutic
4
therapeutic targeting
4
targeting hematologic
4
malignancies historically
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!